When we evaluated peripheral blood by flow cytometry 3 weeks after tumor resection, we found that the percentage of effector memory T cells (CD62L-CD127+ cells) in the CD8+ T cells in peripheral blood was significantly increased in the combination treatment group compared to the vehicle and monotherapy groups, respectively (Figure 4E). The gene discussed is CD8A; the disease is neoplasm.